Proglumide hemicalcium is a non-peptide, orally active cholecystokinin (CCK)-A/B receptor antagonist that selectively blocks the effects of CCK in the central nervous system; it exhibits gastric acid secretion inhibition and gastro-duodenal mucosal protection; additionally, it demonstrates antiepileptic and antioxidant activities.